Are you Dr. Raji?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1 Elliot Way
Elliot Endocrinology
Manchester, NH 03103Phone+1 603-663-3740Fax+1 603-663-3749
Summary
- Dr. Annaswamy Raji, MD is an endocrinologist in Manchester, New Hampshire. She is currently licensed to practice medicine in New Hampshire, Massachusetts, and Vermont. She is affiliated with Veterans Affairs New Jersey Health Care System.
Education & Training
- Brigham and Women's HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1999 - 2000
- University of Vermont Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1998 - 1999
- Wayne State University School of MedicineResidency, Internal Medicine, 1993 - 1996
- Madras Medical CollegeClass of 1987
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- MA State Medical License 2000 - 2026
- NH State Medical License 2008 - 2026
- VT State Medical License 1998 - 2000
- MI State Medical License 1995 - 1999
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Diabetes Recognition Program National Committee for Quality Assurance, 2012-2015
Publications & Presentations
PubMed
- Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.Desiree Abdurrachim, Serene Lek, Charlene Zhi Lin Ong, Chun Kit Wong, Yongqi Zhou
Journal of Hepatology. 2024-11-27 - 6 citationsOverall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National...Tongtong Wang, Yuzhi Xi, Annaswamy Raji, Michael Crutchlow, Gail Fernandes
Annals of Hepatology. 2023-09-22 - 17 citationsGlycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV r...Samuel Dagogo-Jack, Richard E. Pratley, David Z.I. Cherney, Darren K. McGuire, Francesco Cosentino
BMJ Open Diabetes Research & Care. 2021-10-01
Professional Memberships
- 0